A sweeping new review published in Molecular Biology Reports argues that one of the most important drivers of cardiometabolic vascular disease may not be a single molecule, gene or risk factor, but a convergence of physical forces and metabolic stress acting on the endothelium, the delicate single-cell lining of every blood vessel. The work, led by Li Lanlan and Fu Jianhua of Xiyuan Hospital at the China Academy of Chinese Medical Sciences, assembles evidence from human arterial tissue, clinical vascular-function studies, animal models, flow-controlled bioreactor systems and endothelial cell experiments into a unified framework the authors call mechanometabolic endothelial senescence. Their central claim is provocative but carefully hedged: the senescence of endothelial cells, triggered jointly by disturbed blood flow and systemic metabolic load, may act as a disease amplifier that links hypertension, diabetes, kidney disease and fatty liver disease to the stiffening and dysfunction of ageing arteries.

To understand why the framework matters, it helps to start with the physics. Endothelial cells are not passive pipes; they are mechanosensors constantly bathed in shear stress, the frictional force exerted by flowing blood. Where flow is smooth and laminar, endothelial cells align with the flow direction, produce nitric oxide, suppress inflammation and maintain a quiescent, anti-atherogenic state. Where flow is low or oscillatory, typically at arterial branch points and curvatures, the cells experience turbulent, reversing forces that activate inflammatory transcription factors, reprogram metabolism and, critically, induce DNA damage responses. Studies cited in the review show that disturbed flow promotes endothelial senescence through p53-dependent pathways, and that oscillatory shear can activate the STING innate immune pathway, accelerating both senescence and atherosclerosis in experimental models.

The metabolic half of the equation is equally detailed. Hyperglycaemia, dyslipidaemia, uraemic toxins from failing kidneys, hepatic stress from fatty liver disease, inflammatory cytokines such as tumour necrosis factor alpha and oxidative injury all converge on a remarkably consistent set of intracellular targets. These include the p53/p21 and p16/pRB tumour-suppressor axes that enforce cell-cycle arrest, the decline of NAD+ and sirtuin activity that normally protects genomic integrity, mitochondrial dysfunction that floods the cell with reactive oxygen species, and a metabolic rewiring toward glycolysis and altered fatty acid handling. Senescent endothelial cells, the review notes, can even sustain their own inflammatory secretory phenotype, the so-called SASP, through enhanced fatty acid oxidation, creating a self-perpetuating loop of vascular inflammation.

What distinguishes this review from earlier accounts of endothelial ageing is its insistence on the mechanometabolic intersection. Matrix stiffness, which increases as arteries age and stiffen, feeds back on endothelial cells through mechanosensitive channels such as Piezo1, altering their response to shear. Disturbed flow induces metabolic reprogramming via HIF-1alpha and AMPK-driven glycolysis, and single-cell RNA sequencing studies reveal that cells exposed to disturbed flow adopt distinct transcriptomic and chromatin accessibility signatures. Epigenetic mechanisms add another layer: flow-dependent DNA methylation, DNMT1 recruitment, mechanosensitive super-enhancers and even histone lactylation driven by metabolic byproducts all shape which genes an endothelial cell can express. Metabolism, in other words, is not merely fuel; it is a regulator of chromatin, and mechanical forces regulate metabolism.

The authors are explicit that this framework is operational rather than universally standardised. They use cardiometabolic vascular disease, or CMVD, as an umbrella term for vascular injury arising from interacting metabolic, renal and cardiovascular stress, echoing the cardiovascular-kidney-metabolic health concept promoted by the American Heart Association. But they resist the temptation to declare endothelial senescence a universal primary cause of vascular disease. Instead, they describe it as a context-dependent amplifier, a mechanism that magnifies injury where mechanical vulnerability and metabolic load coincide, and a testable translational model whose validity must be demonstrated compartment by compartment.

That translational ambition is where the review becomes most clinically interesting. The authors catalogue the functional anchors clinicians already use: flow-mediated dilatation of the brachial artery for macrovascular endothelial function, carotid-femoral pulse-wave velocity for aortic stiffness, coronary flow reserve and the index of microcirculatory resistance for the coronary microvasculature. Each provides a compartment-specific readout, yet none is a direct senescence assay. To bridge that gap, the review proposes a staged validation strategy that combines confirmation of endothelial identity, convergent senescence markers such as p16, senescence-associated beta-galactosidase and SASP components, measures from circulating endothelial cells or extracellular vesicles, vascular function testing and, ultimately, organ-specific clinical outcomes. Circulating endothelial cells isolated from blood samples, one cited study suggests, could offer a practical window on endothelial senescence without requiring arterial biopsy.

The framework is then stress-tested against three organ contexts. In heart failure with preserved ejection fraction, a condition disproportionately affecting older women, coronary microvascular endothelial inflammation and senescence have been implicated in animal models, and SIRT6 deficiency worsens the diabetic form of the disease in mice, but human evidence remains heterogeneous. In chronic kidney disease, glomerular endothelial senescence drives age-related kidney pathology through plasminogen activator inhibitor-1, and pro-senescent niches organised by matrix proteins such as fibrillin-1 have been described around peritubular capillaries. In metabolic dysfunction-associated steatotic liver disease, aged liver sinusoidal endothelial cells lose their fenestrations and defensive capacity, aggravating hepatic metabolic dysfunction. Across all three, the strongest evidence remains preclinical or mixed translational, a limitation the authors state plainly rather than obscure.

One of the most consequential threads concerns biological sex. Endothelial function declines measurably across the menopause transition, linked to falling estradiol and rising oxidative stress, and nitric oxide itself appears to inhibit endothelial senescence, suggesting a protective mechanism lost after menopause. Yet direct evidence from human arteries complicates the simple story: a study of patients with atherosclerosis found that senescence and inflamm-ageing were associated with endothelial dysfunction in men but not women. The review concludes that sex-disaggregated mechanistic data remain sparse, and that any translational framework claiming general validity must eventually explain why the same senescence machinery may behave differently in female and male vessels.

The therapeutic implications are tantalising but tempered. Senolytic drugs, which clear senescent cells, have ameliorated large-artery stiffening and endothelial dysfunction in aged animals, and habitual exercise in humans is associated with reduced endothelial senescence and better vascular function, partly through enhanced mitophagy in coronary endothelium. NAD+-boosting strategies, sirtuin activation and anti-inflammatory interventions all have preclinical support. But the review’s staged validation strategy is a warning against premature translation: without validated senescence biomarkers in accessible compartments, trials cannot reliably identify which patients carry a mechanometabolic senescence burden or measure whether it has been relieved.

What the review ultimately offers is a map rather than a verdict. It gathers human tissue data, clinical physiology, animal genetics, flow-controlled experiments and single-cell omics into a single causal architecture in which haemodynamic vulnerability and cardiometabolic load jointly push endothelial cells toward senescence, and senescent endothelium in turn stiffens arteries, narrows microvessels and feeds inflammation back into the systemic circulation. The authors’ insistence that the framework is an amplifier, not a universal primary cause, is precisely what makes it scientifically useful: it generates falsifiable predictions about where in the vasculature senescence should accumulate, which biomarkers should track it, and which interventions should relieve it. If those predictions hold in the staged validation the authors propose, the convergence of fluid mechanics and metabolism at the endothelial surface could become one of the organising principles of vascular medicine for the age of cardiometabolic disease.

Subject of Research: Mechanometabolic endothelial senescence linking haemodynamic stress and metabolic load to cardiometabolic vascular disease and vascular ageing

Article Title: Mechanometabolic endothelial senescence as a translational framework for cardiometabolic vascular disease and vascular ageing

Article References: Lanlan, L., Fan, G., Ran, Z., Xiaoqing, Z., Yitong, C., Jingjing, Z., Lei, L., & Jianhua, F. (2026). Mechanometabolic endothelial senescence as a translational framework for cardiometabolic vascular disease and vascular ageing. Molecular Biology Reports, 53(1), Article 1683. https://doi.org/10.1007/s11033-026-12792-w

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12792-w

Keywords: endothelial senescence, mechanotransduction, disturbed flow, vascular ageing, cardiometabolic disease, SASP, sirtuins, arterial stiffness, HFpEF, chronic kidney disease, MASLD, sex differences